小剂量利妥昔单抗辅助重组人血小板生成素联合激素方案治疗免疫性血小板减少症  

Low- dose Rituximab- Assisted Recombinant Human Thrombopoietin Combined with Hormone Therapy for Immune Thrombocytopenia

作　　者：鱼强[1] 刘岐焕[1] 

机构地区：[1]湖北医药学院附属东风总医院血液风湿科,十堰442000

出　　处：《血栓与止血学》2016年第2期151-153,共3页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的分析小剂量利妥昔单抗辅助重组人血小板生成素联合激素治疗免疫性血小板减少症。方法随机双盲法将70例免疫性血小板减少症患者分为两组,各35例,对照组采取重组人血小板生成素联合地塞米松治疗,观察组在对照组基础上加以小剂量利妥昔单抗干预,对两组临床疗效、不良反应、治疗前后血小板计数、凝血功能进行比较。结果观察组总有效率97.1%,高于对照组的82.9%（P0.05）。结论小剂量利妥昔单抗辅助重组人血小板生成素联合激素方案治疗免疫性血小板减少症疗效明确,无严重不良反应,安全可行。Objective To analyze low-dose rituximab-assisted recombinant human thrombopoietin combined with hormone therapy for immune thrombocytopenia. Methods According to the randomized double-blind method,70 patients with immune thrombocytopenia were divided into two groups with 35 cases in each group. The control group was treated with recombinant human thrombopoietin combined with dexamethasone while the observation group,based on the control group,was additionally treated with low-dose rituximab intervention. The clinical curative effect,adverse reaction,platelet count before and after the treatment and blood coagulation function were compared between the two groups. Results The total effective rate of the observation group was 97. 1% which was significantly higher than 82. 9% of the control group. The difference was statistically significant（ P〈0. 05）. After 2 weeks and 4 weeks of treatment,PLT in the observation group was（ 165. 7 ± 10. 8） × 10~9/ L and（ 186. 4 ± 10. 5） × 10~9/ L,respectively which was significantly higher than（ 98. 2± 11. 3） × 10~9/ L and（ 126. 7 ± 10. 8） × 10~9/ L in the control group. The differences were statistically significant（ P 〈 0. 01）. After the treatment,there was no significant difference in the levels of Hgb,PT,a PTT and Fbg and the incidence rate of adverse reactions（ P〉〈0. 05） in the two groups. Conclusion The curative effect of low-dose rituximab-assisted recombinant human thrombopoietin combined with hormone therapy for immune thrombocytopenia is clear and there is no serious adverse reactions. It is safe and feasible.

关 键 词：利妥昔单抗 重组人血小板生成素 地塞米松 免疫性血小板减少症 

分 类 号：R558.2[医药卫生—血液循环系统疾病]